What Enema Casen Treats: Main Uses and Benefits

This section explains the clinical situations and symptom patterns that this product is generally used to manage, focusing on the patient's expected benefit. The sodium phosphate combination in this product is classified as a saline laxative, a category generally indicated for symptomatic relief of certain conditions.

This therapeutic intervention is commonly used to manage symptoms related to physical discomfort in conditions characterized by periods of heightened symptoms, including acute, occasional constipation, fecal impaction, and pre-procedural cleansing before certain diagnostic tests or surgeries.

“This product is applied when short-term symptomatic assistance is needed to help ease discomfort from retained fecal matter.”

Easing Distress from Acute Bowel Retention

This medication is applied in situations involving acute, occasional constipation, which is generally characterized by symptoms such as hard, dry stool, straining, and infrequent elimination. The therapeutic benefit is to offer supportive, timely symptomatic assistance from the immediate discomfort and physical distress caused by retained fecal matter, assisting with maintaining a sense of stability. It is also considered relevant in conditions presenting with significant symptomatic burden, such as fecal impaction. This use supports the patient during difficult episodes by easing distress and may assist with symptomatic clearance when symptoms become more disruptive during flare-ups.

---

Quick Fact: Symptomatic Support for Severe Retention

Essential Symptomatic Support for Medical Procedures

A major therapeutic domain is its commonly used role in pre-procedural cleansing, specifically to prepare the lower bowel before diagnostic examinations (like sigmoidoscopy) or certain colorectal surgeries. This use is applied in clinical settings that involve acute or unstable symptom patterns where symptomatic support for clearance is often needed for procedural considerations, contributing to easing distress during the medical process.

Regulatory References

1. officially used for symptomatic relief

Who Can and Cannot Use Enema Casen?

The eligibility for using this sodium phosphate enema is strictly defined by regulatory authorities to prevent potentially serious complications related to fluid and electrolyte imbalances. Eligibility is determined by age, pre-existing conditions, and overall health status.

Populations for Whom Use is Approved

Age Group	Eligibility Status
Adults and Children 12 years and older	Approved for use under standard conditions.
Children 2 to under 12 years	Conditional use; must use a pediatric-sized product.

Contraindicated and Restricted Use Populations

This medicine must not be used (Contraindicated) by children under 2 years of age or patients with known or suspected Gastrointestinal (GI) obstruction, Bowel perforation, Toxic megacolon, or Severe renal impairment.

Use is restricted and requires consultation with a healthcare professional for the following groups due to increased risk of complications:

• Individuals 55 years of age or older.
• Patients with pre-existing kidney disease or heart problems.
• Patients who are currently dehydrated or on a sodium-restricted diet.

Additionally, if you are pregnant or breastfeeding, consult a health professional before use.

Interactions with Other Medicines and Products: Enema Casen (Sodium Phosphate Rectal)

This section details officially documented interactions for the sodium phosphate enema, focusing on risks related to electrolyte imbalance and altered drug absorption, as outlined in government regulatory labeling.

---

Pharmacodynamic Interactions (Electrolyte and Renal Risk)

Concomitant use with certain drug classes may significantly increase the risk of severe electrolyte disturbances (hyperphosphatemia, hypocalcemia) and acute kidney injury (AKI).

Interaction Type	Interacting Products	Interaction Context
Increased AKI/Electrolyte Risk	Diuretics, ACE Inhibitors, ARBs, NSAIDs, Lithium	Requires caution, especially in the elderly and those with impaired renal function.
Contraindicated Combination	Other oral or rectal sodium phosphate preparations	Avoid co-administration due to toxic risk of hyperphosphatemia.

---

Pharmacokinetic/Timing Interactions

Administration of the enema can accelerate gastrointestinal transit, affecting the body's exposure to other medications.

Interaction Type	Interacting Products	Requirement
Impaired Absorption	General Oral Medications	Separate administration by at least one to two hours to ensure proper absorption and efficacy of oral medications.

No specific interactions with food, alcohol, or herbal products are explicitly documented for the rectal route in official regulatory documents. Population-specific warnings emphasize the heightened risk of interaction-related complications in patients over 55 and those with pre-existing renal disease.

How Enema Casen Works

Enema Casen's action is governed by its ability to engage specific receptor- and enzyme-mediated signaling pathways within the targeted physiological system. The drug initiates a cascade of molecular events, leading to a localized modulation of overactive or dysregulated processes, ultimately resulting in a modification of the system's baseline state.

---

Modulation of Specific Signaling Transmitters

Enema Casen acts within domains involving receptor-mediated signaling, primarily by affecting systems where specific transmitters or mediators dominate. This action initiates or suppresses signaling sequences that control the overall level of pathway activity, contributing to a reduction in the magnitude of overactive pathway signaling by modulating the level of mediator activity.

---

Regulation of Dysregulated Pathway Activity

The drug engages mechanisms that regulate overactive or dysregulated processes, allowing it to be used to alter pathway activity that may escalate under certain conditions. It modifies early molecular steps that influence feedback regulation within these pathways, which results in altered feedback regulation within targeted pathways, leading to changes in downstream physiological parameters.

Official Administration and Dosage Guidelines

This medication is a ready-to-use rectal solution intended strictly for rectal use and must not be swallowed. It is administered as a single, measured dose for acute, intermittent use, not for prolonged therapy. The official instructions mandate a short-term use pattern.

---

Dosing Schedule and Frequency

Age Group	Standard Single Dose	Frequency Constraint
Adults and Children 12+	One bottle (typically 118 mL)	Single daily dosage; Do not use more than once in 24 hours.
Children 2 to under 12 years	Use Pediatric Enema or 1/2 adult bottle	Single daily dosage.
Children under 2 years	DO NOT USE	Absolute restriction.

---

Procedural Timing and Constraints

The product is intended for short-term use, with official guidelines specifying that it should not be used for more than 3 days unless directed by a health professional.

Administration involves a short retention time; the solution typically produces a bowel movement within 1 to 5 minutes of insertion, and retention beyond 5 minutes is generally not required for effect. To ensure proper effect and avoid potential drug interactions, this product should be administered two or more hours before or after other oral medications. To support hydration during use, consuming additional liquids by mouth is recommended.

Research Evidence / Overview of Studies for Enema Casen

---

Evidence for Use in Pre-Procedural Cleansing

Research examined this product's use for acute lower bowel preparation and observed outcomes in Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted primarily in healthy adult populations undergoing procedures like sigmoidoscopy. Research explored whether the product examined lower bowel clearance outcomes necessary for the doctor to perform the test. Outcomes related to physical discomfort and patient-reported experiences were monitored.

Studies report patterns observed in the trials regarding the quality of bowel cleansing in the lower segment. Research highlights changes measured during the short study period, documenting that bowel evacuation was measured following administration. However, when comparing this formulation to high-volume oral preparations, findings were mixed regarding the overall quality of cleansing for examinations of the whole large intestine.

---

Research Examining Use in Acute, Occasional Constipation

This section will review scientific literature, comprised primarily of observational studies and case reports, that has documented the use of this product for acute symptom outcomes in conditions characterized by constipation and fecal impaction.

Studies monitored outcomes describing episodic or acute changes in bowel function, such as the time elapsed until the first evacuation and the physical clearance of retained stool. The available data show patterns related to evacuation was measured within defined time intervals following administration. However, comparative evidence is lacking from large-scale RCTs that directly compare this product against all other types of non-phosphate immediate-acting laxatives specifically for simple, occasional constipation.

---

Evidence in Special Populations and Uncertainties

Research was evaluated in specific age groups, including children and older adults. For instance, pediatric studies explored outcomes related to physical discomfort and time to evacuation. For older adults and those with comorbid conditions, research typically involves observational studies that monitored physiological strain or stress.

Subgroup findings are uncertain due to the nature of the research, and sample sizes were modest in many cases. The research confirms that the degree of certainty regarding the extent of potential systemic changes is lower when attempting to generalize beyond controlled settings. Long-term effects are not fully established, as the product was studied solely for episodic or acute changes.

Key Studies & References Sodium Phosphate Monobasic and Sodium Phosphate Dibasic Rectal Solution Therapeutic Description (DailyMed / NLM)

Common questions about Enema Casen (FAQ)

Q: Can I drink alcohol while taking Pregabalin?

Official product information states that consuming alcohol while taking this medicine is not recommended. Alcohol can intensify the medicine's effects on your nervous system, potentially leading to increased dizziness and drowsiness. Regulatory warnings state that patients should avoid or limit alcohol intake during treatment.

---

Q: Does this medicine cause drowsiness or affect driving?

Regulatory documents indicate that this medicine can cause side effects such as dizziness and somnolence (strong drowsiness). These effects may impact your reaction time and ability to focus. Due to the possibility of these effects, the official product labeling advises caution when driving or operating machinery.

---

Q: Does Pregabalin cause withdrawal symptoms if I stop taking it?

Stopping this medicine suddenly or too quickly may lead to discontinuation symptoms. These have included insomnia, headache, anxiety, nausea, and excessive sweating. The dose should be reduced gradually over a period of at least one week, as outlined in official guidelines, to minimize the risk of these effects.

---

Q: What should I do if I am a diabetic patient taking Pregabalin?

For patients with diabetes, treatment with this medicine has been associated with weight gain in some cases. Official documents note that an adjustment to blood sugar-lowering medicines may be needed in diabetic patients who experience weight gain during treatment.

---

Q: Is this medicine approved for children under 18 years old?

The approval status for children depends on the condition being treated. For the treatment of partial-onset seizures, this medicine is approved as an add-on therapy for patients as young as one month old. However, official information states that it is not approved for nerve pain or fibromyalgia in anyone younger than 18 years of age.

---

Q: Is it safe to use this medicine during pregnancy or while breastfeeding?

Official sources indicate that there is limited data on using this medicine during pregnancy. Official information indicates that use during pregnancy should only occur if the benefit clearly outweighs the potential risk to the fetus. Since the medicine passes into human breast milk, a decision regarding discontinuing either nursing or the medicine is required, considering its importance to the mother.

How to Store and Dispose of Enema Casen

The official storage requirements for this sodium phosphate enema focus on temperature control and product integrity.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store at controlled room temperature, typically between 15°C and 30°C (59°F and 86°F).
Prohibited Storage	The product must not be refrigerated or frozen.
Packaging	Do not use if the bottle is open or if the carton seal is broken.
Child Safety	Keep the enema out of the sight and reach of children.
Stability	The product is for single-use only and any unused portion must be immediately discarded.

Disposal Instructions

Any unused or expired enema product must be disposed of in accordance with local regulations. The best method is often a drug take-back program. If a program is unavailable, follow official guidelines for mixing the medicine with an undesirable substance before sealing and placing it in household trash.